Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 1 35 versus MINZOYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 1 35 versus MINZOYA.
CYCLAFEM 1/35 vs MINZOYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
Intravenous infusion of 300 mg over 30 minutes every 4 weeks.
None Documented
None Documented
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Terminal elimination half-life of 20-30 hours; at steady state after 5-7 days, half-life reflects accumulation for once-daily dosing.
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Primarily hepatic metabolism with renal excretion of metabolites (50-60% as unchanged drug and conjugates); approximately 30-40% fecal elimination.
Category C
Category C
Oral Contraceptive
Oral Contraceptive